One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Horizon Therapeutics PLC before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Horizon Therapeutics PLC’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Horizon Therapeutics PLC’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Horizon Therapeutics PLC (HZNP)

Before we jump into Horizon Therapeutics PLC’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Horizon Therapeutics plc is a global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. The Company operates through two segments: orphan segment and the inflammation segment. The orphan segment includes medicines, such as TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase injection), RAVICTI (glycerol phenylbutyrate), PROCYSBI (cysteamine bitartrate), UPLIZNA (inebilizumab-cdon) injection, ACTIMMUNE (interferon gamma-1b) injection, BUPHENYL (sodium phenylbutyrate) tablets and powder, and QUINSAIR (levofloxacin) solution. The inflammation segment includes medicines, such as PENNSAID (diclofenac sodium topical solution), RAYOS (prednisone), VIMOVO (naproxen), and DUEXIS (ibuprofen).

Want to learn more about Horizon Therapeutics PLC’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Horizon Therapeutics PLC. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Horizon Therapeutics PLC’s Stock Price as of Market Close

As of May 17, 2023, 4:00 PM CST, Horizon Therapeutics PLC’s stock price was $100.51.

Horizon Therapeutics PLC is up 4.33% from its previous closing price of $96.34.

During the last market session, Horizon Therapeutics PLC’s stock traded between $90.56 and $97.00. Currently, there are 228.40 million shares of Horizon Therapeutics PLC stock available for purchase.

Horizon Therapeutics PLC’s price-earnings (P/E) ratio is currently at 60.8, which is high compared to the Pharmaceuticals industry median of 18.3. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Horizon Therapeutics PLC Stock Price History

Horizon Therapeutics PLC’s (HZNP) price is currently down 9.58% so far this month.

During the month of May, Horizon Therapeutics PLC’s stock price has reached a high of $112.76 and a low of $90.56.

Over the last year, Horizon Therapeutics PLC has hit prices as high as $113.83 and as low as $57.84. Year to date, Horizon Therapeutics PLC’s stock is down 6.73%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Horizon Therapeutics PLC Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 16, 2023, there were 2 analysts who downgraded Horizon Therapeutics PLC’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Horizon Therapeutics PLC’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Horizon Therapeutics PLC’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Horizon Therapeutics PLC (HZNP) by visiting AAII Stock Evaluator.

Relative Price Strength of Horizon Therapeutics PLC

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of May 16, 2023, Horizon Therapeutics PLC has a weighted four-quarter relative price strength of 1.99%, which translates to a Momentum Score of 73 and is considered to be Strong.

Want to learn more about how Horizon Therapeutics PLC is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Horizon Therapeutics PLC Stock Price: Bottom Line

As of May 17, 2023, Horizon Therapeutics PLC’s stock price is $100.51, which is up 4.33% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Horizon Therapeutics PLC’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.